Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.
The Association of the British Pharmaceutical Industry has put forward proposals for a “Voluntary Scheme for Pricing, Access and Growth” (VPAG), with a sales rebate of just 6.88%, to replace the current voluntary scheme, which expires at the end of 2023 and has a rebate rate of 26.5% for this year.
The proposals aim to help ensure the life sciences industry contributes to UK economic growth, that the provision of medicines...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
